Stem cell-derived cardiomyocytes (SC-CMs) represent a promising cell source for cardiac regenerative medicine, disease modeling, and drug screening. However, their clinical translation faces significant challenges, including functional immaturity, poor long-term survival, and inadequate integration with host tissue following transplantation. The immune microenvironment, particularly the dynamic polarization of macrophages into pro-inflammatory (M1) or reparative (M2) phenotypes, is increasingly recognized as a critical regulator of cardiac repair, yet a systematic understanding of its specific effects on SC-CM fate remains incomplete. This review aims to comprehensively evaluate the dual regulatory roles of M1 and M2 macrophages on the differentiation efficiency, structural and functional maturation, and in vivo transplantation efficacy of SC-CMs. A systematic literature search was conducted in PubMed, Web of Science, Nature, and CNKI for relevant studies published from database inception to July 2025. After screening, 92 articles were included for analysis. The synthesized evidence demonstrates that M1 macrophages and their secreted factors (e.g., TNF-α, IL-1β) impede cardiac differentiation by inhibiting the Wnt/β-catenin pathway, disrupt sarcomeric organization and calcium handling, and maintain SC-CMs in a glycolytic, immature state. In contrast, M2 macrophages enhance SC-CM maturation by providing trophic support (e.g., IGF-1, HGF), promoting electrophysiological maturation and metabolic reprogramming towards oxidative phosphorylation, and facilitating angiogenesis via VEGF. The novelty of this review lies in its integrated perspective on macrophage-driven immunomodulation as a central axis for SC-CM maturation. Furthermore, it discusses emerging therapeutic strategies—such as optimized transplantation timing, co-transplantation with immunomodulatory cells, engineered exosomes, and smart biomaterials—that leverage macrophage polarization to create a favorable microenvironment for SC-CMs. Ultimately, harnessing macrophage-SC-CM crosstalk is a crucial step toward advancing clinically effective and immunologically informed cardiac regeneration therapies.
Cervical cancer is the fourth-ranked malignant tumor of female cancer in the world, and it seriously threatens women’s health. The main treatment options for patients with cervical cancer are surgery or concurrent chemoradiotherapy. With the development of medical research, researchers are committed to exploring more effective and specific treatment options in order to increase the treatment options for cervical cancer and improve the treatment effect. Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) technology is a method in which the Cas9 protein uses guide RNA (gRNA) to target the target gene and achieve precise editing of the target gene. At present, CRISPR/Cas9 technology has become a promising and powerful gene editing tool, a new and effective targeted therapy that has been applied in the treatment of various tumors. The research progress of CRISPR/Cas9 technology in the treatment of cervical cancer is mainly reviewed in terms of action targets, combination therapy strategies, and related drug resistance gene screening in order to provide new strategies for the treatment of cervical cancer.
Tumor immunotherapy has become the main treatment method for cancer after surgery, radiotherapy and chemotherapy. With the in-depth study of tumor immunology, cell biology and molecular technology, the tumor microenvironment was found to be immunosuppressive, and tumor development and metastasis are closely related to it. Tumor immunotherapy uses the body’s own immune system to kill tumor cells. At present, there are mainly mainstream tumor immunotherapy methods, namely monoclonal antibody therapy, immune checkpoint inhibitor therapy, immunocell therapy, and tumor vaccines. In this paper, the advantages and limitations of these four immunotherapies were mainly discussed, and the current status of their marketing and clinical research was also reviewed.
Objective:To investigate the expression of maternal embryonic leucine zipper kinase (MELK) in renal clear cell carcinoma and its relationship with clinical and pathological characteristics of the patients with renal clear cell carcinoma, and to evaluate its effect on the proliferation of renal clear cell carcinoma.Methods:The expression of MELK in renal clear cell carcinoma and its relationship with the overall survival of patients was analyzed using the gene expression profiling interactive analysis (GEPIA) online database. Cancer tissue samples from 77 patients with renal clear cell carcinoma treated at Xinxiang Central Hospital were collected, all of which have been confirmed as renal clear cell carcinoma through immunohistochemistry experiments. The relationship between the expression of MELK in renal clear cell carcinoma tissue and the clinical and pathological characteristics of the patients was analyzed. The effect of MELK on the proliferation of renal clear cell carcinoma cells was explored through cloning experiments and CCK-8 assay.Results:Information from the GEPIA database revealed that the expression level of the MELK gene was upregulated in renal clear cell carcinoma compared with normal tissues. The clinicopathological analysis results showed that MELK expression was significantly correlated with tumor size and diameter of renal clear cell carcinoma ( P < 0.05), and had no statistically significant correlation with patient age, gender, or tumor differentiation. The results of the clonogenic assay and the CCK-8 assay showed that MELK expression promoted the proliferation of renal clear cell carcinoma cells (all P < 0.05). Conclusions:MELK promotes the proliferation of kidney cancer cells, which may provide a new therapeutic strategy for the treatment of renal clear cell carcinoma.
The radiomics of tumors can indirectly reflect the state of tumor proteins and even genes. The radiomics extract imaging features through high-throughput and conduct correlation analysis to play a role in predicting tumor stage, pathological differentiation, therapeutic efficacy, and prognosis. In this review paper, relevant literature about the research progress of radiomics in the prediction of esophageal cancer stage, lymphovascular invasion, pathological differentiation, short-term curative effect, and long-term prognosis is summarized.
